TransMedics Group, Inc. (NASDAQ:TMDX) is Sandhill Capital Partners LLC’s 3rd Largest Position

Sandhill Capital Partners LLC raised its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 4.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 763,201 shares of the company’s stock after buying an additional 30,591 shares during the period. TransMedics Group makes up about 5.0% of Sandhill Capital Partners LLC’s portfolio, making the stock its 3rd biggest holding. Sandhill Capital Partners LLC’s holdings in TransMedics Group were worth $60,239,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Harbour Capital Advisors LLC boosted its position in shares of TransMedics Group by 1.7% during the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock worth $627,000 after buying an additional 140 shares during the period. RiverPark Advisors LLC raised its stake in shares of TransMedics Group by 19.5% in the fourth quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after acquiring an additional 215 shares in the last quarter. Park Avenue Securities LLC raised its stake in shares of TransMedics Group by 3.9% in the third quarter. Park Avenue Securities LLC now owns 11,729 shares of the company’s stock valued at $642,000 after acquiring an additional 442 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of TransMedics Group by 7.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,396 shares of the company’s stock valued at $584,000 after acquiring an additional 483 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of TransMedics Group by 39.0% in the third quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock valued at $116,000 after acquiring an additional 597 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward M. Basile sold 7,157 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total value of $618,221.66. Following the transaction, the director now directly owns 8,350 shares in the company, valued at approximately $721,273. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 117,078 shares of company stock valued at $9,972,971. 6.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TMDX has been the topic of several analyst reports. Morgan Stanley increased their price objective on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. raised their price target on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Piper Sandler began coverage on TransMedics Group in a research note on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price target on the stock. Finally, Oppenheimer raised their price target on TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

TransMedics Group Stock Performance

Shares of TMDX stock traded up $0.37 during mid-day trading on Thursday, hitting $89.25. 444,257 shares of the stock were exchanged, compared to its average volume of 685,106. The stock’s fifty day simple moving average is $82.94 and its two-hundred day simple moving average is $74.12. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $99.63. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.22. The company had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The business’s quarterly revenue was up 158.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.21) earnings per share. On average, research analysts forecast that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.